Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 1 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingNCT07885293Phase 3
- Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic SyndromeNot yet recruitingNCT07819396Phase 2
- Asciminib Frontline Risk AdaptedNot yet recruitingNCT07804901Phase 2
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNot yet recruitingNCT07758218Phase 1
- Study of CD38 and CD56 in Chronic Myeloid LeukemiaNot yet recruitingNCT07740603
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf RegionNot yet recruitingNCT07681258
- Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI TreatmentRecruitingNCT07651878Phase 1
- Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent LinesNot yet recruitingNCT07640750
- Impact of Targeted Therapy on Cancer-Related Cognitive ImpairmentRecruitingNCT07638007
- A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyRecruitingNCT07549516
- ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)Not yet recruitingNCT07538401Phase 2
- Safety and Tolerability of ZE74-0282 in Healthy VolunteersRecruitingNCT07527221Phase 1
- ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid LeukemiaNot yet recruitingNCT07518940Not applicable
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) PatientsNot yet recruitingNCT07489755Phase 3
- A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in KuwaitNot yet recruitingNCT07454850
- Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia PatientsNot yet recruitingNCT07413263
- Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseEnrolling by invitationNCT07383298
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTRecruitingNCT07302776Phase 1
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRecruitingNCT07269470Phase 2
- Prophylactic DLI-X for Leukemia Relapse After HCTNot yet recruitingNCT07254793Phase 1
- Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorRecruitingNCT07238712Phase 2
- Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology NetworkRecruitingNCT07165535
- Identification of BCR::ABL1 Mutations by Digital PCR in CMLNot yet recruitingNCT07158294Not applicable
- Expression Pattern and Possible Clinical Significance of CD81 In Myeloid LeukemiaNot yet recruitingNCT07146542
- HPC Offered for PRESERVE ExpansionRecruitingNCT07145411
- A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaRecruitingNCT07061145
- A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasRecruitingNCT06994676Phase 1
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
- Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid LeukemiaNot yet recruitingNCT06865443
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationRecruitingNCT06859424Phase 2
- Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibRecruitingNCT06817720Phase 2
- ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsRecruitingNCT06787144Phase 1
- Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CMLRecruitingNCT06724536
- A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive LeukemiaNot yet recruitingNCT06672263Phase 1
- Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT TrialEnrolling by invitationNCT06646978
- Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingNCT06532084Phase 2
- Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)Not yet recruitingNCT06530810Phase 1
- Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.RecruitingNCT06514534Phase 2
- Vitamin A and D Supplementation in Allogeneic HCTRecruitingNCT06508099Phase 2
- TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) PatientsRecruitingNCT06453902Phase 2
- Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingNCT06423911Phase 3
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPRecruitingNCT06390306
- Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialRecruitingNCT06355583Phase 2
- The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia PatientsRecruitingNCT06301321
- A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).RecruitingNCT06297161
- Chronic Kidney Disease Patient in Chronic Myloied LeukemiaNot yet recruitingNCT06266975
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT06236724Phase 2
- Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid LeukemiaRecruitingNCT06229860
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)RecruitingNCT06163430Phase 1/2
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted TherapyRecruitingNCT06130787Not applicable
- Ponatinib in Chronic Myeloid Leukemia Patients in Chronic PhaseRecruitingNCT06119269
- TGRX-678 US Phase I for Chronic Myelogenous Leukemia PatientsRecruitingNCT06088888Phase 1
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- Chronic Myeloid Leukemia (CML) Real-Life DatabaseRecruitingNCT05963061
- Asciminib RMP StudyRecruitingNCT05943522
- Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic PhaseRecruitingNCT05926128Not applicable
- Ex Vivo Drug Sensitivity Testing and Multi-Omics ProfilingRecruitingNCT05857969Phase 1
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- CML Pediatric ITK Response According to Molecular Identification at DiagnosisRecruitingNCT05605379
- Treatment Free Remission (TFR) in CML Patients （CML-CP）StudyNot yet recruitingNCT05440747
- Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free RemissionRecruitingNCT05439889
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingNCT05367765Phase 4
- A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.RecruitingNCT05367700Phase 1
- A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT05353205Phase 4
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069
- A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaRecruitingNCT05304377Phase 1
- Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid LeukemiaRecruitingNCT05282108
- Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid LeukemiaRecruitingNCT05130138Not applicable
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruitingNCT04925479Phase 1/2
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingNCT04838041Phase 2
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingNCT04835584Phase 1/2
- Italian Treatment Free Remission RegistryRecruitingNCT04769947
- Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT04739826
- Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid LeukemiaNot yet recruitingNCT04709731Phase 2
- Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or DasatinibRecruitingNCT04681820
- Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy AdherenceRecruitingNCT04663100Not applicable
- Managed Access Programs for ABL001, AsciminibAvailableNCT04360005
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingNCT04260022Phase 1
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- European CML Blast Crisis RegisterRecruitingNCT03869502
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingNCT03595917Phase 1
- Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideRecruitingNCT03533816Phase 1
- EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase InhibitorsRecruitingNCT03481868Not applicable
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsRecruitingNCT03459534Phase 3
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
- Selumetinib and Azacitidine in High Risk Chronic Blood CancersRecruitingNCT03326310Phase 1
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- Second STOP After Pioglitazone Priming in CML PatientsRecruitingNCT02889003Phase 2